|
|
 |
|
Viewing report
|
|
|
|
Emerging Therapies for Diabetes (Technical Insights)
Frost & Sullivan, Sep 2006
This Frost & Sullivan research service titled Emerging Therapies in Diabetes provides in-depth information about the various commercial products and therapies for diabetes and related health complications, available in the market today and those on the verge of commercialization. In this research service, Frost & Sullivan's expert analysts thoroughly examine the following applications: drug therapy, insulin therapy, pancreas transplant, islet cell therapy, artificial pancreas, and gene therapy.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sector in this research:
- Obesity
Technologies
The following technologies are covered in this research:
- Pharmacotherapy
- Insulin Therapy
- Pancreas Transplant
- Islet Cell Transplant
- Artificial Pancreas
- Gene Therapy
Technology Overview
The Escalating Rate of Diabetes is Encouraging the Development of New Therapies
The twin diseases of diabetes and obesity, now being referred to as diabesity, is becoming a global epidemic and one of the leading causes of mortality around the world. Managing the disease to have satisfactory patient outcomes depends largely on the early detection of the disease, the number of diabetic patients actually undergoing diabetic screening, and a specific course of therapeutic treatment.
Pharmaceutical companies have started focusing on novel agents and therapies that treat diabetes by unique mechanisms. Unlike the current drugs, which may cause toxic side effects, these new drugs are agents that improve or replicate metabolic actions of insulin to overcome insulin resistance, preserve beta-cell function, and prevent loss of beta cells, observes the analyst of this research service. These drugs, which would be capable of multiple actions by treating both diabetes and related complications, are soon likely to be commercialized.
Methods of Insulin Delivery Evolving to Meet Patients’ Needs
Modern types of insulin that suit individual needs and innovative delivery methods for noninvasive insulin therapy have been developed to meet the growing need of patients requiring daily insulin doses. There is an increasing demand for simplified procedures to restore normal insulin levels for controlling blood sugar. This has led to the development of islet cell therapies using sophisticated technology called the Edmonton protocol. This is largely preferred to pancreas transplants.
Another recent development has been the artificial pancreas, which consists of a glucose sensor, insulin pump, and computer software that connects the two to enable automated monitoring, dose adjustments, and insulin infusion without patient intervention. Vast research and developmental studies are being carried out to perfect gene therapy, which is likely to offer a complete solution for both prevention and cure for diabetes, notes the analyst. The application of nanotechnology in future glucose sensing devices, artificial pancreas research, and gene delivery techniques can significantly boost further developments in this sector.
|
|
|
|
